**Figure 3. Change From Baseline in HDRS-17 Total Score (Post Hoc Analysis) in Patients Receiving Zuranolone 30 mg/d With (A) Baseline HDRS-17 Total Score ≥ 24, (B) Measurable Drug Levels, and (C) Baseline HDRS-17 Total Score ≥ 24 Plus Measurable Drug Levels**


A. Patients With Baseline HDRS-17 Total Score ≥ 24[a]

	0	3	8	12	15	21	28	35	42	70	126	182
Placebo	n = 115	115	110	107	104	108	104	102	99	75	71	65
Zuranolone 30 mg	n = 124	122	121	116	115	111	111	105	100	76	70	66

B. Patients With Measurable Drug Levels[b]

	0	3	8	12	15	21	28	35	42	70	126	182
Placebo	n = 157	157	152	147	141	146	142	141	135	101	94	88
Zuranolone 30 mg	n = 151	148	145	140	139	136	135	129	124	94	85	81

C. Patients With Baseline HDRS-17 Total Score ≥ 24 Plus Measurable Drug[c]

	0	3	8	12	15	21	28	35	42	70	126	182
Placebo	n = 115	115	110	107	104	108	104	102	99	75	71	65
Zuranolone 30 mg	n = 115	113	112	108	107	104	103	98	94	72	66	62

[a]Model used was the mixed effects for repeated measures with treatment (zuranolone 30 mg, zuranolone 20 mg, or placebo), baseline HDRS-17 total score, SOC antidepressant use at baseline (Yes or No), assessment time point, and time point–by-treatment interaction as fixed effects with unstructured covariance structure. Secondary and post hoc analyses were not adjusted for multiplicity. Shaded area indicates 14-day treatment period.
[b]Model used was the mixed effects for repeated measures with treatment (zuranolone 30 mg, zuranolone 20 mg, or placebo), baseline HDRS-17 total score, SOC antidepressant use at baseline (Yes or No), assessment time point, and time point–by-treatment interaction as fixed effects with unstructured covariance structure. Secondary and post hoc analyses were not adjusted for multiplicity.
[c]Model used was the mixed effects for repeated measures with treatment (zuranolone 30 mg, zuranolone 20 mg, or placebo), baseline HDRS-17 total score, SOC antidepressant use at baseline (Yes or No), assessment time point, and time point–by-treatment interaction as fixed effects with unstructured covariance structure. Secondary and post hoc analyses were not adjusted for multiplicity.
*$P < .05$ vs placebo. †$P < .01$ vs placebo. ‡$P < .0025$ vs placebo.
Abbreviations: HDRS-17 = 17-item Hamilton Depression Rating Scale total score, LSM = least-squares mean, n = number of patients on that day, SOC = standard of care.